



**Technology Brief: Plasma Protein Biomarkers for Diagnosis of Ovarian Cancer**

Docket Number: 06B098

<p><b>Summary</b></p>	<ul style="list-style-type: none"> <li>• There is a great need for a reliable way to diagnose ovarian cancer, especially in the early stages.</li> <li>• Analysis of markers in blood offers many advantages in terms of cost and ease of sampling.</li> <li>• Researchers at Moffitt Cancer Center have identified a panel of 21 proteins from patient plasma that correlate with ovarian cancer.</li> </ul>
<p><b>Features and Benefits</b></p>	<ul style="list-style-type: none"> <li>• The 21 proteins are differentially expressed in plasma, affording easy sampling from the patient.</li> <li>• The panel is based on a large sample size of 160 women, improving reliability of the results.</li> <li>• Eight of the proteins are differentially expressed in early stage ovarian cancer, where there is a great need for a reliable test.</li> <li>• The protein panel offers promise as a clinical test for diagnosis, screening and monitoring therapy in ovarian cancer.</li> </ul>
<p><b>Stage of Development</b></p>	<p>An assay is being developed for clinical validation studies.</p>
<p><b>Inventors</b></p>	<p>Drs. R. Sutphen and J. Lancaster</p>
<p><b>Patents</b></p>	<p>Patent application pending.</p>
<p><b>Contact Information:</b></p> <p style="text-align: center;"> <b>Haskell Adler PhD MBA</b>          Senior Licensing Manager          Email: <a href="mailto:haskell.adler@moffitt.org">haskell.adler@moffitt.org</a>          Telephone: 813-745-6596       </p> <p style="text-align: center;"> <b>H. Lee Moffitt Cancer Center and Research Institute, Inc.</b>          Office of Technology Management and Commercialization          12902 Magnolia Drive MRC-TTO          Tampa, FL 33612          Website: <a href="http://www.moffitt.org/OTMC">http://www.moffitt.org/OTMC</a> </p>	